Learn about the factors that influence the choice between chemotherapy re-challenge and the combination of lenvatinib and pembrolizumab for endometrial cancer treatment in the context of clinical data.
Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, discuss the prevalence of patients with recurrent endometrial cancer, challenges in responding to chemotherapy, and the potential for improved treatment options in the second-line setting.
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE for First-Line Treatment of ER+ miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Pfizer Inc. today announced overall survival results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® in combination with letrozole compared to placebo plus letrozole for the. | June 4, 2022